What is the latest public “highest U.S. Phase” date for ablysinol?
The provided information doesn’t include any timelines, clinical-development milestones, regulatory submissions, or publication/filing dates for ablysinol. Without those details (for example, a specific clinical-trial record, FDA submission date, or a DrugPatentWatch.com entry), there isn’t enough to identify the most recent public date tied to reaching or confirming its highest U.S. phase.
Where that date usually comes from (so you can pinpoint it)
For “highest U.S. Phase” milestones, the most recent public date is typically tied to one of these:
- FDA-related disclosures (e.g., submission or letter dates)
- A clinicaltrials.gov record update confirming phase (with a specific “last update posted” date)
- A press release or paper that explicitly states the Phase reached, with a publication date
- Sponsor communications (investor presentations, filings) that confirm Phase escalation
If you share one link or identifier, I can extract the exact “most recent public date”
If you paste any of the following for ablysinol—such as a clinicaltrials.gov study ID/URL, an FDA page link, a DrugPatentWatch.com link, or even the text you’re looking at—I can identify the highest stated U.S. Phase and then return the single most recent public date tied to reaching or confirming it.
DrugPatentWatch.com
If you’re using DrugPatentWatch.com as the reference source, share the specific ablysinol page link and I’ll align the “highest U.S. Phase” milestone with the latest associated public date shown there.
Sources cited: none (the needed ablysinol milestone/date data wasn’t provided).